SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Miscellaneous >

InMed Pharmaceuticals Inc. (IMLFF)

Add IMLFF Price Alert      Hide Sticky   Hide Intro
Moderator: stockman69, lesgetrich, NetworkNewsWire
Search This Board: 
Last Post: 3/23/2017 1:49:32 PM - Followers: 142 - Board type: Free - Posts Today: 0

A drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids

InMed Pharmaceuticals, Inc. (OTCQB: (IMLFF; CSE: IN) is a preclinical-stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems. InMed conducts research, discovery, pre-clinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. The three core asset groups of the Company, namely, the bioinformatics database assessment tool, the biosynthesis manufacturing process, and the drug development programs serves as InMed's fundamental value drivers.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents while developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of $1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

Investment Highlights

  • Extensive portfolio of assets in dermatology, ocular disease and additional indications and cannabinoid biosynthesis
    Positioned to achieve value-driving, near-term corporate milestones with limited investment
    Led by a management team of experienced professionals capable of building value in biopharmaceuticals



Bioinformatics: a significant promise for future drug discovery

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis.

With this tool, InMed aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases.

After discovering active cannabinoids, InMed tests and confirms their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company's proprietary biosynthesis process of cannabinoid manufacturing will be most promising.

InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.



InMed is building a robust product pipeline through its proprietary discovery platform and research & product development programs. The company continues to seek innovative product candidates for the treatment in following therapeutic areas:

  • Ocular Diseases
    Pain & Inflammation
  • CNS
    Respiratory Disease
    Metabolic Disease

InMed's pipeline currently includes two drug candidates in preclinical development: INM-750 for the treatment of epidermolysis bullosa (EB); and INM-085 for the treatment of glaucoma.


Referred to as "The Worst Disease You've Never Heard Of," EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States.

INM-750 is a proprietary, topical cannabinoid product candidate intended as a dual approach therapy that may prove beneficial to patients in two ways: first, the ability of certain cannabinoids to play a role in addressing key disease hallmarks (wound healing, infection, pain, itch, inflammation); and second, the ability of some cannabinoids to regulate the expression of various proteins incriminated in EB's pathogenesis by upregulating certain keratins in the skin in an effort to modulate the painful manifestations of EB.

Through the development of INM-750, InMed's lead program, InMed is attempting to address this significant unmet medical need, in this Orphan indication, for which there is no approved treatment or cure.

Market Potential - Amicus Therapeutics recently acquired Scioderm, Inc. and its lead EB drug candidate, Zorblisa™, for $847 million. Notably, Scioderm's sole clinical asset was Zorblisa.

JP Morgan and Cowen Research Reports estimate that peak sales for Zorblisa could reach $900 million to $1.2 billion.


INM-085 is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration of this dual action approach to treatment. Additionally, InMed is developing a proprietary once-a day hydro-gel, an important drug delivery technology for this therapy. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure.

Market Potential - The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease. Worldwide, glaucoma represents a market of $5.6 billion.


The Case for Cannabinoids

The majority of pharmaceutical and academic research & development activities being performed with cannabis revolves around the understanding of its biologically active ingredients, the cannabinoids.

Currently there are 90+ cannabinoids that have been isolated from cannabis, each affecting the body's cannabinoid receptors and responsible for unique pharmacological effects. There are currently two known types of cannabinoid receptors, called CB1 and CB2.

CB1 receptors are primarily found in the brain and central nervous system, and to a lesser extent in other issues.

CB2 receptors are mostly in the peripheral organs, especially cells associated with the immune system.

Cannabinoids can be administered by smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Once in the body, most cannabinoids are metabolized in the liver, although some is stored in fat.

Cannabinoids can be separated from the plant by extraction with organic solvents. However, to produce high purity, cannabinoid chemical synthesis or semisynthesis is generally required.

InMed specializes in developing novel therapies through the R&D into the extensive pharmacology of cannabinoids in combination with innovative drug delivery systems, positioning the company as a unique first-mover in the cannabis-pharma sector.



InMed's management team and board of directors have well over a century of combined experience in the biopharmaceutical space. Together, the professionals comprising this team are guiding InMed into exciting opportunities in the cannabis-pharma sector.

Eric A. Adams, President & CEO
Eric Adams is a seasoned biopharmaceutical executive with over 25 years of experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.

He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana aerospace industry, most recently with Metal Form, Inc., a privately held aerospace manufacturing company, where he served as president and CEO from 1987 to September of 1999.

Dr. Sazzad Hossain, Ph.D., M.Sc., Chief Scientific Officer
Dr. Sazzad Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.

Dr. Ado Muhammed, MD, DPM, MFPM, Chief Medical Officer
Dr. Ado Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs. His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role and others at GW Pharmaceuticals, Dr. Muhammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. Dr. Muhammed's received his MD at Ahmadu Bello University followed by an MSc in Orthopaedics at University College London. Dr. Muhammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff followed by an MBA in Business Administration at the University of Leicester. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.

Alexandra D.J. Mancini, M.Sc., Senior Vice President, Clinical and Regulatory Affairs
Alexandra Mancini has over 30 years of global biopharmaceutical R&D experience with a particular emphasis on clinical development and regulatory affairs. Mancini has been an executive with several biotech companies, overseeing a wide range of drug development activities. As Sr. VP of Clinical & Regulatory Affairs at Sirius Genomics, her role included identifying and managing external resources for medical expertise in sepsis; clinical data management; and statistical theory, programming and analyses. While at INEX Pharmaceuticals as Sr. VP of Clinical & Regulatory Affairs, Mancini oversaw Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance for oncology. She served as VP of Regulatory Affairs at QLT Inc. for oncology and ocular diseases, playing a significant role in the development of VISUDYNER from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Mancini also led the regulatory approval process for the anticancer drug PHOTOFRINR and its associated medical devices, the first drug-device combination product approved by the US Food and Drug Administration. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.

Martin Bott, Director
Martin Bott has over 28 years of experience in senior financial and executive leadership. He currently serves as VP of Corporate Finance and Investment Banking at Eli Lilly & Company. He joined Lilly in 1988 and has held roles of increasing responsibility at their headquarters in Indianapolis as well as affiliates in Switzerland, Germany, and the UK. Prior to his current assignment, Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations. He has been a member of the Lilly CFO Staff since December 2002. Bott has a Bachelor of Business / Marketing (Cologne, Germany, 1985) and a Master's in International Business Studies (University of South Carolina, 1988).

Andrew Hull, Director
Andrew Hull has over 30 years of experience in various commercial and business development roles with leading pharmaceutical and biotech companies. He currently serves as Vice President of Global Alliances for Takeda Pharmaceuticals where he is responsible for maximizing the success of Takeda's growing number (40+) of commercial and R&D partnerships with many of the industry's leading pharmaceutical and biotech companies. In previous roles, he led marketing and commercial development of Takeda's US portfolio of over $3 billion including diabetes, neuroscience, GI and cardiovascular therapies. Additionally, he held positions of increasing responsibility at Immunex and Abbott Labs. Hull received a bachelor's degree in biology from Kenyon College in 1985. He serves as a member of the Board of Directors of the Illinois Biotechnology Industry Organization and is a member of the Kenyon College Board of Trustees.

For a full listing of individuals on InMed's management team, Board of Directors and Scientific Advisory Board visit:


InMed Pharmaceuticals, Inc.
#350-409 Granville Street
Vancouver, BC
Canada V6C 1T2
Phone: (604) 669-7207

1324 Lexington Ave.
Suite 117
New York, NY 10128
Phone: (212) 418-1217


NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website:




InMed Pharmaceuticals is a drug discovery and development company uniquely
focused on the therapeutic potential of cannabinoids.



InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

Corporate Presentation



InMed Pharmaceuticals is currently developing two products in its drug pipeline: INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma.


Epidermolysis Bullosa (EB) is group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily from friction or trauma. Internal organs and bodily systems can also be affected by EB. It is a result in a defect of anchoring between the dermis and epidermis cause most frequently by the absence of certain keratins (or, proteins) in the skin. EB is an orphan disease with no currently approved treatments and has a significant unmet medical need. INM-750 will potentially be the first therapy designed and developed specifically to modulate disease activity and to alleviate symptoms in EB.

INM-750 includes multiple cannabinoids as the active ingredients:

The cannabinoids included in INM-750 were selected to modulate keratin levels in patients with EB with the expectation of having a disease modulating effect
A secondary consideration in selection of the cannabinoids was addressing symptoms of EB such as inflammation, wound healing, skin regeneration, itching, and pain
INM-750 is being developed for topical application, designed to maximize penetration of the cannabinoids to the epidermal / dermal junction in the skin.



Glaucoma is a group of eye disorders which result in damage of the optic nerve. The damage is most often caused by an abnormally high pressure in the eye and is one of the leading causes of blindness in the developed world.

INM-085 will be the first ever glaucoma treatment developed that is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. The cannabinoids in INM-085 have been selected to reduce the elevated intra-ocular pressure (IOP) in the affected eyes and provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues.

INM-085 is designed as a topical formulation to be administered directly to the eye. The formulation that has been designed by InMed is a proprietary polymer-based formulation to facilitate absorption of the cannabinoids into the eye while also being well tolerated by the patients. We envision a once-a-day application, at bedtime, to deliver effective dose levels of INM-085.



Bioinformatics: Proprietary Drug / Disease Targeting Tool

InMed’s has developed a computer-based program to assist in the identification of novel cannabinoids using: (i) comprehensive algorithms to integrate data from numerous bioinformatics databases, (ii) a database on the structure of currently approved pharmaceutical products, and (iii) an extensive database on over 90 individual cannabinoid drugs found in cannabis.

InMed’s data included in its bioinformatics assessment tool are derived from both public and propriety based sources, and include information on:
Protein-Protein interactions
Gene Regulation
Epigenetic modification
Cell signal networks, and

InMed uses processes called “random walk algorithms” and “guilt by association” to establish gene and protein-protein interaction networks to identify multi-target based approaches for therapy development for specific diseases.By using its comprehensive pharmaceutical and cannabinoid structures database, and by creating associations between approved pharmaceuticals (whose pharmacodynamics effects are well characterized) and cannabinoids with similar structures, InMed identifies active cannabinoids to act on above mentioned genes and proteins.Once a series of potentially active cannabinoids are identified for a specific disease target, InMed will test and confirm their activity in biological systems with 
in vitro and in vivo
 experimentation.This type of bioinformatics assessment, as a general approach, represents significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.



Proposed Targets to Develop Drugs From Cannabis and Other Botanical Sources


Epidermolysis Bullosa
Pachyonychia Congenital
Epidermolytic Ichthyosis
Pemphigus Vulgaris


Ocular Allergies

Pain and Inflammation

Orofacial Pain
Rheumatoid Arthritis


Huntington’s Disease





Metabolic Disease


Metabolic Syndrome


University of British Columbia
Department of Chemical & Biological Engineering
Vancouver Campus
2360 East Mall
Vancouver, BC Canada V6T 1Z3

Department of Pharmaceutical Sciences
Vancouver Campus
2405 Westbrook Mall
Vancouver, BC, Canada V6T 1Z3

University of Debrecen
Research Center for Molecular Medicine, Department of Physiology
1H-4032 Debrecen, Nagyerdei krt. 98





Cap Structure (as of Tue Jan, 1, 2017)
Issued & Outstanding 93.1 Million
Warrants 14.1 Million
Options 14.7 Million
Fully-Diluted 121.9 Million
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
IMLFF News: Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth 03/15/2017 09:30:00 AM
IMLFF News: InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex 03/02/2017 09:00:00 AM
IMLFF News: InMed Engages Peter Mountford as Strategic Advisor 05/05/2015 04:00:00 AM
IMLFF News: InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S. 04/30/2015 11:00:00 AM
IMLFF News: InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy 04/15/2015 06:00:00 AM
#1259  Sticky Note Interview with InMed CEO Eric Adams on company goals lesgetrich 12/22/16 10:57:01 PM
#2250   Agreed Bobin 03/23/17 01:49:32 PM
#2249   Just some speculation, but can you imagine the tr1205 03/23/17 12:47:43 PM
#2248   Wrong again. The RVV term sheet with InMed Bobin 03/23/17 12:41:26 PM
#2247   This is not news. It is another in Bobin 03/23/17 12:38:12 PM
#2246   Dr Friedman is a leader in the field tr1205 03/23/17 12:21:05 PM
#2245   NEWS MARCH 22 OUT OF EUROPE ON INMED tr1205 03/23/17 12:15:34 PM
#2244   So many things Brewing for this Company!!! TooYoungToDie 03/23/17 11:16:02 AM
#2243   My background is in US Securities and I'm lesgetrich 03/23/17 09:46:41 AM
#2242   InMed Receives Exemption Status from Health Canada rosie10 03/23/17 09:17:17 AM
#2241   I'm going nuts with anticipation after the Forbes Matilda1 03/22/17 10:22:31 PM
#2240   “NI 44-101” Short term prospectus intent filed by Bobin 03/22/17 05:03:55 PM
#2239   This thing is a ticking time bomb$$$$ TooYoungToDie 03/22/17 02:25:39 PM
#2238   InMed's Exceptional Management Team Executes Ambitious Plan -- SVX95 03/22/17 10:37:48 AM
#2237 Vinpat 03/21/17 06:55:34 PM
#2236   That article identifies the difference between InMed's biosynthesis lesgetrich 03/21/17 05:18:29 PM
#2235   InMed Pharmaceuticals Forbes Article March 21 2017 rosie10 03/21/17 03:15:35 PM
#2234   I just don't get the point of it lesgetrich 03/21/17 02:13:23 PM
#2233   Thank you I saw these before, I just Vinpat 03/20/17 10:51:48 PM
#2232   This is from their PR a year ago... lesgetrich 03/20/17 10:30:26 PM
#2231   Teewinot is doing biosynthesis for several companies which Vinpat 03/20/17 05:04:58 PM
#2230   Everyone is doing biosynthesis now so not sure lesgetrich 03/20/17 04:54:59 PM
#2229   By my estimation, Nemus is about 2 years Vinpat 03/20/17 03:15:30 PM
#2228   Provisional patents have to be re-filed after one year... lesgetrich 03/20/17 11:01:03 AM
#2227   Regarding patents, there are reasons that a pending lesgetrich 03/20/17 10:51:10 AM
#2226   Last week's patent talk got me intrigued, so frozenspokes 03/20/17 10:00:59 AM
#2225   Perspectus needed when company offers stock to public. SamL67 03/19/17 06:00:56 PM
#2224   Filed Mar 14th. What is this filing used for? Bobin 03/19/17 12:38:20 PM
#2223   Intent to file short term perspectus distribution. What? SamL67 03/19/17 08:54:53 AM
#2222   It doesn't look like they have any patents. Vinpat 03/18/17 08:07:22 PM
#2221   Well good luck. If you learn anything on Bobin 03/18/17 05:43:21 PM
#2220   I'm pretty new to this stock and am TASBES0101 03/18/17 05:38:53 PM
#2219   what somebody needs to do is attend one bigideaportugal 03/18/17 04:31:00 PM
#2218   I search the Canada patent office but was TASBES0101 03/18/17 04:19:49 PM
#2217   Have you considered that they may have applied lesgetrich 03/18/17 04:17:29 PM
#2216   Don't hold your breath. Its virtually impossible to Bobin 03/18/17 04:09:45 PM
#2215   I've asked the company about patents but haven't TASBES0101 03/18/17 03:51:57 PM
#2213   Very true. They continue to dilute while pushing Bobin 03/18/17 11:09:58 AM
#2212   In early 2015, Inmed was telling investors they TASBES0101 03/18/17 08:53:06 AM
#2211   Never gna happen without a financing deal. Theyv Bobin 03/17/17 09:42:38 PM
#2210   I honestly believe this can become a $10 shortorlong 03/17/17 07:41:03 PM
#2208   Sorry, but looking at these patents more closely TASBES0101 03/17/17 03:15:41 AM
#2207   I found 53 patents for Inmed in the TASBES0101 03/17/17 03:01:03 AM
#2206   According to the CEO, they haven't shown they Vinpat 03/17/17 02:39:19 AM
#2205 TASBES0101 03/17/17 02:02:19 AM
#2204   Questions regarding patents for their glaucoma and EB Vinpat 03/16/17 09:04:47 PM
#2203   Invested almost a year ago and wish I Brykad 03/16/17 08:10:30 PM
#2202   IMLFF Lead Product Candidate Targeting Rare, Incurable Skin Disease NetworkNewsWire 03/16/17 01:20:14 PM
#2201   NetworkNewsWire Announces Publication of Discussion on the R&D SVX95 03/16/17 09:39:16 AM
#2200   looking good..... 1upandaway 03/15/17 03:32:23 PM
#2199   Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth NetworkNewsWire 03/15/17 08:59:32 AM